End Stage Renal Disease Drug - Global and China Top Players Market Share and Ranking 2023
According to Latest Research, the global market for End Stage Renal Disease Drug should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China End Stage Renal Disease Drug market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029. The United States End Stage Renal Disease Drug market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By segment, End Stage Renal Disease Induced Hyperparathyroidism grew percent to account for percent of the total market sales, and End Stage Renal Disease Induced Hyperphosphatemia grew percent.
End-stage kidney disease drugs are used widely to treat end-stage kidney disease also known as the late stage renal disease, which occurs when chronic kidney disease reaches an advanced state. In this stage, the kidneys can no longer work, as they should to meet the body's needs. It damages the nephron and the kidney cannot function to remove the waste product from the body. The disease can cause other severe problems such as kidney failure, hypertension, brain aneurysm, and chronic pain.
This report studies and analyses global End Stage Renal Disease Drug status and future trends, helps the client to determine the End Stage Renal Disease Drug market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for End Stage Renal Disease Drug, and provides market size (in K Units & US$ million) and Year-over-Year growth, considering 2022 as the base year.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
To assess the competitive environment within the market including supplier revenue, market share, and company profiles.
Highlights
(1) Global End Stage Renal Disease Drug market size, history data 2018-2023, and forecast data 2024 -2029, (US$ million) & (K Units)
(2) Global End Stage Renal Disease Drug sales, revenue, price by company, market share and industry ranking 2018-2023, (US$ million) & (K Units)
(3) China End Stage Renal Disease Drug sales, revenue, price by company, market share and industry ranking 2018-2023, (US$ million) & (K Units)
(4) Global End Stage Renal Disease Drug key consuming regions, consumption quantity, consumption value and demand structure
(5) Global End Stage Renal Disease Drug key producing regions, capacity, production, and year over year growth
(6) End Stage Renal Disease Drug industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Pfizer Inc
AstraZeneca
Bristol-Myers Squibb Company
Dr. Reddy's Laboratories Ltd
Endo International plc
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Mylan NV
Novartis AG
Lupin
Cipla Inc
Aurobindo Pharma
Fresenius SE & Co. KGaA
Sanofi
Takeda Pharmaceutical Company Limited
F. Hoffmann-La Roche Ltd
Kissei Pharmaceutical Co., Ltd
Abbott
Market segment by Type, covers
Calcimimetics
Vitamin D
Sterols
Potassium Binders
Calcium-Based Phosphate Binders
Other
Market segment by Application, can be divided into
End Stage Renal Disease Induced Hyperparathyroidism
End Stage Renal Disease Induced Hyperphosphatemia
End Stage Renal Disease Induced Hyperkalaemia
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe End Stage Renal Disease Drug product scope, global sales quantity, value and average price, China sales quantity, value and average price, development opportunities, challenges, trends, and policies.
Chapter 2: Global End Stage Renal Disease Drug market share and ranking of major manufacturers, sales quantity, revenue, average price, 2018-2023
Chapter 3: China End Stage Renal Disease Drug market share and ranking of major manufacturers, sales quantity, revenue, average price, 2018-2023
Chapter 4: Global key producing regions of End Stage Renal Disease Drug, percent & CAGR, 2018-2029
Chapter 5: End Stage Renal Disease Drug industry chain, upstream, medium-stream, and downstream.
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2018-2029
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2018-2029
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2018-2029
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2018-2029
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin.
Chapter 11: Conclusions
1 Market Overview
1.1 End Stage Renal Disease Drug Definition
1.2 Global End Stage Renal Disease Drug Market Size and Forecast
1.2.1 By Consumption Value, Global End Stage Renal Disease Drug Market Size，2018-2029
1.2.2 By Sales Quantity, Global End Stage Renal Disease Drug Market Size，2018-2029
1.2.3 Global End Stage Renal Disease Drug Average Selling Price (ASP)，2018-2029
1.3 China End Stage Renal Disease Drug Market Size and Forecast
1.3.1 By Consumption Value, China End Stage Renal Disease Drug Market Size，2018-2029
1.3.2 By Sales Quantity, China End Stage Renal Disease Drug Market Size，2018-2029
1.3.3 China End Stage Renal Disease Drug Average Selling Price (ASP)， 2018-2029
1.4 Share of China End Stage Renal Disease Drug Market with Respect to the Global Market
1.4.1 By Consumption Value, China End Stage Renal Disease Drug Market Share in Global, 2018-2029
1.4.2 By Sales Quantity, China End Stage Renal Disease Drug Market Share in Global, 2018-2029
1.4.3 End Stage Renal Disease Drug Market Size: China VS Global, 2018-2029
1.5 End Stage Renal Disease Drug Market Dynamics
1.5.1 End Stage Renal Disease Drug Market Drivers
1.5.2 End Stage Renal Disease Drug Market Restraints
1.5.3 End Stage Renal Disease Drug Industry Trends
1.5.4 End Stage Renal Disease Drug Industry Policy
2 Global Leading Manufacturers and Market Share
2.1 By Revenue of End Stage Renal Disease Drug, Global Market Share by Company, 2018-2023
2.2 By Sales Quantity of End Stage Renal Disease Drug, Global Market Share by Company, 2018-2023
2.3 End Stage Renal Disease Drug Average Selling Price (ASP) by Company, 2018-2023
2.4 Global End Stage Renal Disease Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global End Stage Renal Disease Drug Concentration Ratio
2.6 Global End Stage Renal Disease Drug Mergers & Acquisitions, Expansion Plans
2.7 Global End Stage Renal Disease Drug Manufacturers Product Type
2.8 Head Office and End Stage Renal Disease Drug Production Site of Key Manufacturer
2.9 End Stage Renal Disease Drug Capacity of Major Manufacturers and Future Plan
3 China Leading Manufacturers and Market Share
3.1 By Revenue of End Stage Renal Disease Drug, China Market Share by Company, 2018-2023
3.2 By Sales Quantity of End Stage Renal Disease Drug, China Market Share by Company, 2018-2023
3.3 China End Stage Renal Disease Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Global Producing Regions
4.1 Global End Stage Renal Disease Drug Capacity, Output and Capacity Utilization, 2018-2029
4.2 Global End Stage Renal Disease Drug Capacity by Region
4.3 Global End Stage Renal Disease Drug Production & Forecast by Region, 2018 VS 2022 VS 2029
4.4 Global End Stage Renal Disease Drug Production by Region, 2018-2029
4.5 Global End Stage Renal Disease Drug Production Market Share & Forecast by Region, 2018-2029
5 Industry Chain Analysis
5.1 End Stage Renal Disease Drug Industry Chain
5.2 End Stage Renal Disease Drug Upstream Analysis
5.2.1 End Stage Renal Disease Drug Core Raw Materials
5.2.2 Main Manufacturers of End Stage Renal Disease Drug Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 End Stage Renal Disease Drug Production Mode
5.6 End Stage Renal Disease Drug Procurement Model
5.7 End Stage Renal Disease Drug Industry Sales Model and Sales Channels
5.7.1 End Stage Renal Disease Drug Sales Model
5.7.2 End Stage Renal Disease Drug Typical Distributors
6 Sights by Type
6.1 End Stage Renal Disease Drug Classification
6.1.1 Calcimimetics
6.1.2 Vitamin D
6.1.3 Sterols
6.1.4 Potassium Binders
6.1.5 Calcium-Based Phosphate Binders
6.1.6 Other
6.2 By Type, Global End Stage Renal Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029
6.3 By Type, Global End Stage Renal Disease Drug Consumption Value, 2018-2029
6.4 By Type, Global End Stage Renal Disease Drug Sales Quantity, 2018-2029
6.5 By Type, Global End Stage Renal Disease Drug Average Selling Price (ASP), 2018-2029
7 Sights by Application
7.1 End Stage Renal Disease Drug Segment by Application
7.1.1 End Stage Renal Disease Induced Hyperparathyroidism
7.1.2 End Stage Renal Disease Induced Hyperphosphatemia
7.1.3 End Stage Renal Disease Induced Hyperkalaemia
7.2 By Application, Global End Stage Renal Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029
7.3 By Application, Global End Stage Renal Disease Drug Consumption Value, 2018-2029
7.4 By Application, Global End Stage Renal Disease Drug Sales Quantity, 2018-2029
7.5 By Application, Global End Stage Renal Disease Drug Price, 2018-2029
8 Sales Sights by Region
8.1 By Region, Global End Stage Renal Disease Drug Consumption Value, 2018 VS 2022 VS 2029
8.2 By Region, Global End Stage Renal Disease Drug Consumption Value, 2018-2029
8.3 By Region, Global End Stage Renal Disease Drug Sales Quantity, 2018-2029
8.4 North America
8.4.1 North America End Stage Renal Disease Drug & Forecasts, 2018-2029
8.4.2 By Country, North America End Stage Renal Disease Drug Market Size Market Share
8.5 Europe
8.5.1 Europe End Stage Renal Disease Drug Market Size & Forecasts, 2018-2029
8.5.2 By Country, Europe End Stage Renal Disease Drug Market Size Market Share
8.6 Asia Pacific
8.6.1 Asia Pacific End Stage Renal Disease Drug Market Size & Forecasts, 2018-2029
8.6.2 By Country/Region, Asia Pacific End Stage Renal Disease Drug Market Size Market Share
8.7 South America
8.7.1 South America End Stage Renal Disease Drug Market Size & Forecasts, 2018-2029
8.7.2 By Country, South America End Stage Renal Disease Drug Market Size Market Share
8.8 Middle East & Africa
9 Sales Sights by Country Level
9.1 By Country, Global End Stage Renal Disease Drug Market Size & CAGR, 2018 VS 2022 VS 2029
9.2 By Country, Global End Stage Renal Disease Drug Consumption Value, 2018-2029
9.3 By Country, Global End Stage Renal Disease Drug Sales Quantity, 2018-2029
9.4 U.S.
9.4.1 U.S. End Stage Renal Disease Drug Market Size, 2018-2029
9.4.2 By Type, U.S. End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.4.3 By Application, U.S. End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.5 Europe
9.5.1 Europe End Stage Renal Disease Drug Market Size, 2018-2029
9.5.2 By Type, Europe End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.5.3 By Application, Europe End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.6 China
9.6.1 China End Stage Renal Disease Drug Market Size, 2018-2029
9.6.2 By Type, China End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.6.3 By Application, China End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.7 Japan
9.7.1 Japan End Stage Renal Disease Drug Market Size, 2018-2029
9.7.2 By Type, Japan End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.7.3 By Application, Japan End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.8 South Korea
9.8.1 South Korea End Stage Renal Disease Drug Market Size, 2018-2029
9.8.2 By Type, South Korea End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.8.3 By Application, South Korea End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.9 Southeast Asia
9.9.1 Southeast Asia End Stage Renal Disease Drug Market Size, 2018-2029
9.9.2 By Type, Southeast Asia End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.9.3 By Application, Southeast Asia End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.10 India
9.10.1 India End Stage Renal Disease Drug Market Size, 2018-2029
9.10.2 By Type, India End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.10.3 By Application, India End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.11 Middle East & Africa
9.11.1 Middle East & Africa End Stage Renal Disease Drug Market Size, 2018-2029
9.11.2 By Type, Middle East & Africa End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.11.3 By Application, Middle East & Africa End Stage Renal Disease Drug Sales Quantity Market Share, 2022 VS 2029
10 Manufacturers Profile
10.1 Pfizer Inc
10.1.1 Pfizer Inc Company Information, Head Office, Market Area, and Industry Position
10.1.2 Pfizer Inc End Stage Renal Disease Drug Models, Specifications, and Application
10.1.3 Pfizer Inc End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.1.4 Pfizer Inc Company Profile and Main Business
10.1.5 Pfizer Inc Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
10.2.2 AstraZeneca End Stage Renal Disease Drug Models, Specifications, and Application
10.2.3 AstraZeneca End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.2.4 AstraZeneca Company Profile and Main Business
10.2.5 AstraZeneca Recent Developments
10.3 Bristol-Myers Squibb Company
10.3.1 Bristol-Myers Squibb Company Company Information, Head Office, Market Area, and Industry Position
10.3.2 Bristol-Myers Squibb Company End Stage Renal Disease Drug Models, Specifications, and Application
10.3.3 Bristol-Myers Squibb Company End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.3.4 Bristol-Myers Squibb Company Company Profile and Main Business
10.3.5 Bristol-Myers Squibb Company Recent Developments
10.4 Dr. Reddy's Laboratories Ltd
10.4.1 Dr. Reddy's Laboratories Ltd Company Information, Head Office, Market Area, and Industry Position
10.4.2 Dr. Reddy's Laboratories Ltd End Stage Renal Disease Drug Models, Specifications, and Application
10.4.3 Dr. Reddy's Laboratories Ltd End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.4.4 Dr. Reddy's Laboratories Ltd Company Profile and Main Business
10.4.5 Dr. Reddy's Laboratories Ltd Recent Developments
10.5 Endo International plc
10.5.1 Endo International plc Company Information, Head Office, Market Area, and Industry Position
10.5.2 Endo International plc End Stage Renal Disease Drug Models, Specifications, and Application
10.5.3 Endo International plc End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.5.4 Endo International plc Company Profile and Main Business
10.5.5 Endo International plc Recent Developments
10.6 Teva Pharmaceutical Industries Ltd
10.6.1 Teva Pharmaceutical Industries Ltd Company Information, Head Office, Market Area, and Industry Position
10.6.2 Teva Pharmaceutical Industries Ltd End Stage Renal Disease Drug Models, Specifications, and Application
10.6.3 Teva Pharmaceutical Industries Ltd End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.6.4 Teva Pharmaceutical Industries Ltd Company Profile and Main Business
10.6.5 Teva Pharmaceutical Industries Ltd Recent Developments
10.7 Sun Pharmaceutical Industries Ltd
10.7.1 Sun Pharmaceutical Industries Ltd Company Information, Head Office, Market Area, and Industry Position
10.7.2 Sun Pharmaceutical Industries Ltd End Stage Renal Disease Drug Models, Specifications, and Application
10.7.3 Sun Pharmaceutical Industries Ltd End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.7.4 Sun Pharmaceutical Industries Ltd Company Profile and Main Business
10.7.5 Sun Pharmaceutical Industries Ltd Recent Developments
10.8 Mylan NV
10.8.1 Mylan NV Company Information, Head Office, Market Area, and Industry Position
10.8.2 Mylan NV End Stage Renal Disease Drug Models, Specifications, and Application
10.8.3 Mylan NV End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.8.4 Mylan NV Company Profile and Main Business
10.8.5 Mylan NV Recent Developments
10.9 Novartis AG
10.9.1 Novartis AG Company Information, Head Office, Market Area, and Industry Position
10.9.2 Novartis AG End Stage Renal Disease Drug Models, Specifications, and Application
10.9.3 Novartis AG End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.9.4 Novartis AG Company Profile and Main Business
10.9.5 Novartis AG Recent Developments
10.10 Lupin
10.10.1 Lupin Company Information, Head Office, Market Area, and Industry Position
10.10.2 Lupin End Stage Renal Disease Drug Models, Specifications, and Application
10.10.3 Lupin End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.10.4 Lupin Company Profile and Main Business
10.10.5 Lupin Recent Developments
10.11 Cipla Inc
10.11.1 Cipla Inc Company Information, Head Office, Market Area, and Industry Position
10.11.2 Cipla Inc End Stage Renal Disease Drug Models, Specifications, and Application
10.11.3 Cipla Inc End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.11.4 Cipla Inc Company Profile and Main Business
10.11.5 Cipla Inc Recent Developments
10.12 Aurobindo Pharma
10.12.1 Aurobindo Pharma Company Information, Head Office, Market Area, and Industry Position
10.12.2 Aurobindo Pharma End Stage Renal Disease Drug Models, Specifications, and Application
10.12.3 Aurobindo Pharma End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.12.4 Aurobindo Pharma Company Profile and Main Business
10.12.5 Aurobindo Pharma Recent Developments
10.13 Fresenius SE & Co. KGaA
10.13.1 Fresenius SE & Co. KGaA Company Information, Head Office, Market Area, and Industry Position
10.13.2 Fresenius SE & Co. KGaA End Stage Renal Disease Drug Models, Specifications, and Application
10.13.3 Fresenius SE & Co. KGaA End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.13.4 Fresenius SE & Co. KGaA Company Profile and Main Business
10.13.5 Fresenius SE & Co. KGaA Recent Developments
10.14 Sanofi
10.14.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
10.14.2 Sanofi End Stage Renal Disease Drug Models, Specifications, and Application
10.14.3 Sanofi End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.14.4 Sanofi Company Profile and Main Business
10.14.5 Sanofi Recent Developments
10.15 Takeda Pharmaceutical Company Limited
10.15.1 Takeda Pharmaceutical Company Limited Company Information, Head Office, Market Area, and Industry Position
10.15.2 Takeda Pharmaceutical Company Limited End Stage Renal Disease Drug Models, Specifications, and Application
10.15.3 Takeda Pharmaceutical Company Limited End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.15.4 Takeda Pharmaceutical Company Limited Company Profile and Main Business
10.15.5 Takeda Pharmaceutical Company Limited Recent Developments
10.16 F. Hoffmann-La Roche Ltd
10.16.1 F. Hoffmann-La Roche Ltd Company Information, Head Office, Market Area, and Industry Position
10.16.2 F. Hoffmann-La Roche Ltd End Stage Renal Disease Drug Models, Specifications, and Application
10.16.3 F. Hoffmann-La Roche Ltd End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.16.4 F. Hoffmann-La Roche Ltd Company Profile and Main Business
10.16.5 F. Hoffmann-La Roche Ltd Recent Developments
10.17 Kissei Pharmaceutical Co., Ltd
10.17.1 Kissei Pharmaceutical Co., Ltd Company Information, Head Office, Market Area, and Industry Position
10.17.2 Kissei Pharmaceutical Co., Ltd End Stage Renal Disease Drug Models, Specifications, and Application
10.17.3 Kissei Pharmaceutical Co., Ltd End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.17.4 Kissei Pharmaceutical Co., Ltd Company Profile and Main Business
10.17.5 Kissei Pharmaceutical Co., Ltd Recent Developments
10.18 Abbott
10.18.1 Abbott Company Information, Head Office, Market Area, and Industry Position
10.18.2 Abbott End Stage Renal Disease Drug Models, Specifications, and Application
10.18.3 Abbott End Stage Renal Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.18.4 Abbott Company Profile and Main Business
10.18.5 Abbott Recent Developments
11 Conclusion
12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer
Table 1. End Stage Renal Disease Drug Consumption Value & CAGR: China VS Global, 2018-2029, US$ Million
Table 2. End Stage Renal Disease Drug Market Restraints
Table 3. End Stage Renal Disease Drug Market Trends
Table 4. End Stage Renal Disease Drug Industry Policy
Table 5. Global End Stage Renal Disease Drug Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022
Table 6. Global End Stage Renal Disease Drug Revenue Share by Company, 2018-2023, Ranked by Data of 2022
Table 7. Global End Stage Renal Disease Drug Sales Quantity by Company, (2018-2023) & (K Units), Ranked Based on Sales in 2022
Table 8. Global End Stage Renal Disease Drug Sales Quantity by Company, 2018-2023, Ranked by Data of 2022
Table 9. Global End Stage Renal Disease Drug Average Selling Price (ASP) by Company, (2018-2023) & (US$/Unit)
Table 10. Global End Stage Renal Disease Drug Manufacturers Market Concentration Ratio (CR3 and HHI)
Table 11. Global End Stage Renal Disease Drug Mergers & Acquisitions, Expansion Plans
Table 12. Global End Stage Renal Disease Drug Manufacturers Product Type
Table 13. Head Office and End Stage Renal Disease Drug Production Site of Key Manufacturer
Table 14. End Stage Renal Disease Drug Capacity of Major Manufacturers and Future Plan
Table 15. China End Stage Renal Disease Drug Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022
Table 16. China End Stage Renal Disease Drug Sales Quantity by Company, (2018-2023) & (K Units), Ranked Based on Sales in 2022
Table 17. China End Stage Renal Disease Drug Sales Quantity by Company, 2018-2023, Ranked by Data of 2022
Table 18. Global End Stage Renal Disease Drug Production & Forecast by Region, 2018 VS 2022 VS 2029, (K Units)
Table 19. Global End Stage Renal Disease Drug Production by Region, 2018-2023, (K Units)
Table 20. Global End Stage Renal Disease Drug Production Forecast by Region, 2024-2029, (K Units)
Table 21. Global Key Players of End Stage Renal Disease Drug Upstream (Raw Materials)
Table 22. Global End Stage Renal Disease Drug Typical Customers
Table 23. End Stage Renal Disease Drug Typical Distributors
Table 24. By Type, Global End Stage Renal Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 25. By Application, Global End Stage Renal Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 26. By Region, Global End Stage Renal Disease Drug Consumption Value, 2018 VS 2022 VS 2029, US$ Million
Table 27. By Region, Global End Stage Renal Disease Drug Consumption Value, 2018-2029, US$ Million
Table 28. By Region, Global End Stage Renal Disease Drug Sales Quantity, 2018-2029, (K Units)
Table 29. By Country, Global End Stage Renal Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 30. By Country, Global End Stage Renal Disease Drug Consumption Value, 2018-2029, US$ Million
Table 31. By Country, Global End Stage Renal Disease Drug Consumption Value Market Share, 2018-2029
Table 32. By Country, Global End Stage Renal Disease Drug Sales Quantity, 2018-2029, (K Units)
Table 33. By Country, Global End Stage Renal Disease Drug Sales Quantity Market Share, 2018-2029
Table 34. Pfizer Inc Company Information, Head Office, Market Area, and Industry Position
Table 35. Pfizer Inc End Stage Renal Disease Drug Models, Specifications, and Application
Table 36. Pfizer Inc End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 37. Pfizer Inc Company Profile and Main Business
Table 38. Pfizer Inc Recent Developments
Table 39. AstraZeneca Company Information, Head Office, Market Area, and Industry Position
Table 40. AstraZeneca End Stage Renal Disease Drug Models, Specifications, and Application
Table 41. AstraZeneca End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 42. AstraZeneca Company Profile and Main Business
Table 43. AstraZeneca Recent Developments
Table 44. Bristol-Myers Squibb Company Company Information, Head Office, Market Area, and Industry Position
Table 45. Bristol-Myers Squibb Company End Stage Renal Disease Drug Models, Specifications, and Application
Table 46. Bristol-Myers Squibb Company End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 47. Bristol-Myers Squibb Company Company Profile and Main Business
Table 48. Bristol-Myers Squibb Company Recent Developments
Table 49. Dr. Reddy's Laboratories Ltd Company Information, Head Office, Market Area, and Industry Position
Table 50. Dr. Reddy's Laboratories Ltd End Stage Renal Disease Drug Models, Specifications, and Application
Table 51. Dr. Reddy's Laboratories Ltd End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 52. Dr. Reddy's Laboratories Ltd Company Profile and Main Business
Table 53. Dr. Reddy's Laboratories Ltd Recent Developments
Table 54. Endo International plc Company Information, Head Office, Market Area, and Industry Position
Table 55. Endo International plc End Stage Renal Disease Drug Models, Specifications, and Application
Table 56. Endo International plc End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 57. Endo International plc Company Profile and Main Business
Table 58. Endo International plc Recent Developments
Table 59. Teva Pharmaceutical Industries Ltd Company Information, Head Office, Market Area, and Industry Position
Table 60. Teva Pharmaceutical Industries Ltd End Stage Renal Disease Drug Models, Specifications, and Application
Table 61. Teva Pharmaceutical Industries Ltd End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 62. Teva Pharmaceutical Industries Ltd Company Profile and Main Business
Table 63. Teva Pharmaceutical Industries Ltd Recent Developments
Table 64. Sun Pharmaceutical Industries Ltd Company Information, Head Office, Market Area, and Industry Position
Table 65. Sun Pharmaceutical Industries Ltd End Stage Renal Disease Drug Models, Specifications, and Application
Table 66. Sun Pharmaceutical Industries Ltd End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 67. Sun Pharmaceutical Industries Ltd Company Profile and Main Business
Table 68. Sun Pharmaceutical Industries Ltd Recent Developments
Table 69. Mylan NV Company Information, Head Office, Market Area, and Industry Position
Table 70. Mylan NV End Stage Renal Disease Drug Models, Specifications, and Application
Table 71. Mylan NV End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 72. Mylan NV Company Profile and Main Business
Table 73. Mylan NV Recent Developments
Table 74. Novartis AG Company Information, Head Office, Market Area, and Industry Position
Table 75. Novartis AG End Stage Renal Disease Drug Models, Specifications, and Application
Table 76. Novartis AG End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 77. Novartis AG Company Profile and Main Business
Table 78. Novartis AG Recent Developments
Table 79. Lupin Company Information, Head Office, Market Area, and Industry Position
Table 80. Lupin End Stage Renal Disease Drug Models, Specifications, and Application
Table 81. Lupin End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 82. Lupin Company Profile and Main Business
Table 83. Lupin Recent Developments
Table 84. Cipla Inc Company Information, Head Office, Market Area, and Industry Position
Table 85. Cipla Inc End Stage Renal Disease Drug Models, Specifications, and Application
Table 86. Cipla Inc End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 87. Cipla Inc Company Profile and Main Business
Table 88. Cipla Inc Recent Developments
Table 89. Aurobindo Pharma Company Information, Head Office, Market Area, and Industry Position
Table 90. Aurobindo Pharma End Stage Renal Disease Drug Models, Specifications, and Application
Table 91. Aurobindo Pharma End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 92. Aurobindo Pharma Company Profile and Main Business
Table 93. Aurobindo Pharma Recent Developments
Table 94. Fresenius SE & Co. KGaA Company Information, Head Office, Market Area, and Industry Position
Table 95. Fresenius SE & Co. KGaA End Stage Renal Disease Drug Models, Specifications, and Application
Table 96. Fresenius SE & Co. KGaA End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 97. Fresenius SE & Co. KGaA Company Profile and Main Business
Table 98. Fresenius SE & Co. KGaA Recent Developments
Table 99. Sanofi Company Information, Head Office, Market Area, and Industry Position
Table 100. Sanofi End Stage Renal Disease Drug Models, Specifications, and Application
Table 101. Sanofi End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 102. Sanofi Company Profile and Main Business
Table 103. Sanofi Recent Developments
Table 104. Takeda Pharmaceutical Company Limited Company Information, Head Office, Market Area, and Industry Position
Table 105. Takeda Pharmaceutical Company Limited End Stage Renal Disease Drug Models, Specifications, and Application
Table 106. Takeda Pharmaceutical Company Limited End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 107. Takeda Pharmaceutical Company Limited Company Profile and Main Business
Table 108. Takeda Pharmaceutical Company Limited Recent Developments
Table 109. F. Hoffmann-La Roche Ltd Company Information, Head Office, Market Area, and Industry Position
Table 110. F. Hoffmann-La Roche Ltd End Stage Renal Disease Drug Models, Specifications, and Application
Table 111. F. Hoffmann-La Roche Ltd End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 112. F. Hoffmann-La Roche Ltd Company Profile and Main Business
Table 113. F. Hoffmann-La Roche Ltd Recent Developments
Table 114. Kissei Pharmaceutical Co., Ltd Company Information, Head Office, Market Area, and Industry Position
Table 115. Kissei Pharmaceutical Co., Ltd End Stage Renal Disease Drug Models, Specifications, and Application
Table 116. Kissei Pharmaceutical Co., Ltd End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 117. Kissei Pharmaceutical Co., Ltd Company Profile and Main Business
Table 118. Kissei Pharmaceutical Co., Ltd Recent Developments
Table 119. Abbott Company Information, Head Office, Market Area, and Industry Position
Table 120. Abbott End Stage Renal Disease Drug Models, Specifications, and Application
Table 121. Abbott End Stage Renal Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 122. Abbott Company Profile and Main Business
Table 123. Abbott Recent Developments
List of Figures
Figure 1. End Stage Renal Disease Drug Picture
Figure 2. Global End Stage Renal Disease Drug Consumption Value, (US$ million) & (2018-2029)
Figure 3. Global End Stage Renal Disease Drug Sales Quantity, (K Units) & (2018-2029)
Figure 4. Global End Stage Renal Disease Drug Average Selling Price (ASP), (2018-2029) & (US$/Unit)
Figure 5. China End Stage Renal Disease Drug Consumption Value, (US$ million) & (2018-2029)
Figure 6. China End Stage Renal Disease Drug Sales Quantity (K Units) & (2018-2029)
Figure 7. China End Stage Renal Disease Drug Average Selling Price (ASP), (US$/Unit) & (2018-2029)
Figure 8. By Consumption Value, China End Stage Renal Disease Drug Market Share of Global, 2018-2029
Figure 9. By Sales Quantity, China End Stage Renal Disease Drug Market Share of Global, 2018-2029
Figure 10. Global End Stage Renal Disease Drug Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2022
Figure 11. China End Stage Renal Disease Drug Key Participants, Market Share, 2022
Figure 12. Global End Stage Renal Disease Drug Capacity, Production and Capacity Utilization, 2018-2029
Figure 13. Global End Stage Renal Disease Drug Capacity Market Share by Region, 2022 VS 2029
Figure 14. Global End Stage Renal Disease Drug Production Market Share & Forecast by Region, 2018-2029
Figure 15. End Stage Renal Disease Drug Industry Chain
Figure 16. End Stage Renal Disease Drug Procurement Model
Figure 17. End Stage Renal Disease Drug Sales Model
Figure 18. End Stage Renal Disease Drug Sales Channels, Direct Sales, and Distribution
Figure 19. Calcimimetics
Figure 20. Vitamin D
Figure 21. Sterols
Figure 22. Potassium Binders
Figure 23. Calcium-Based Phosphate Binders
Figure 24. Other
Figure 25. By Type, Global End Stage Renal Disease Drug Consumption Value, 2018-2029, US$ Million
Figure 26. By Type, Global End Stage Renal Disease Drug Consumption Value Market Share, 2018-2029
Figure 27. By Type, Global End Stage Renal Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 28. By Type, Global End Stage Renal Disease Drug Sales Quantity Market Share, 2018-2029
Figure 29. By Type, Global End Stage Renal Disease Drug Average Selling Price (ASP), 2018-2029, (US$/Unit)
Figure 30. End Stage Renal Disease Induced Hyperparathyroidism
Figure 31. End Stage Renal Disease Induced Hyperphosphatemia
Figure 32. End Stage Renal Disease Induced Hyperkalaemia
Figure 33
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
| Historical Data (2015-2019) |
|
|
| Influencing Factors |
|
|
| Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|